Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis

Table 3 Treatment outcomes of both pan-susceptible TB cases throughout SCC and those acquired drug resistant TB during treatment

Treatment outcomes n(%)	Pan-susceptible TB throughout^a N = 1609	Acquired drug resistant TB N = 62
Treatment outcomes n(%)	Pan-susceptible TB throughout^a N = 1609	≦2 months	3–5 months	Total
Successfully treated	1357(84.3)	44(84.6)	2(20.0)	46(74.1)
Failed	102(6.3)	6(11.5)	7(70.0)	13(21.0)
Died	36(2.2)	0(0.0)	1(10.0)	1(1.6)
Defaulted	39(2.4)	1(1.9)	0(0.0)	1(1.6)
Not evaluated	75(4.7)	1(1.9)	0(0.0)	1(1.6)

^aPan-susceptible TB throughout in our study was defined as cases with TB strains susceptible to all four first-line anti-TB drugs including isoniazid(H), rifampicin (R), ethambutol (E), and streptomycin (S) both pretreatment and throughout the therapy

ISSN: 1471-2466